drugset

drugset / Trial / NCT05695417

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

NCT05695417 ↗

Phase 1 Unknown 21 enrolled Ocular Therapeutix, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Timeline

Start: 2023-01-15
Primary completion: 2024-01
Completion: 2024-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Axitinib	Small molecule	—	Intravitreal

Indications